Guangzhou Kingmed Diagnostics Group (603882) Fundamentals 2026 — Revenue Analysis | SniperIQ
Guangzhou Kingmed Diagnostics Group (603882) is a CN-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ¥12.6B, trading at ¥27.11 on the SHH. This SniperIQ fundamentals page covers Guangzhou Kingmed Diagnostics Group's valuation, profitability (net margin -1.7%), revenue (¥6.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Guangzhou Kingmed Diagnostics Group's market cap?
Guangzhou Kingmed Diagnostics Group (603882) has a market capitalization of approximately ¥12.6B, trading at ¥27.11 on the SHH. Market cap moves with the live share price.
What is Guangzhou Kingmed Diagnostics Group's P/E ratio?
Guangzhou Kingmed Diagnostics Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Guangzhou Kingmed Diagnostics Group?
Guangzhou Kingmed Diagnostics Group runs a net profit margin of -1.7%, a gross margin of 35.1%, and an operating margin of -0.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Guangzhou Kingmed Diagnostics Group generate?
Guangzhou Kingmed Diagnostics Group reported revenue of ¥6.0B for fiscal year 2025, with net income of -¥173M and earnings per share (EPS) of -0.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Guangzhou Kingmed Diagnostics Group pay a dividend?
Guangzhou Kingmed Diagnostics Group offers a trailing dividend yield of about 3.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Guangzhou Kingmed Diagnostics Group financially healthy?
Guangzhou Kingmed Diagnostics Group carries a debt-to-equity ratio of 0.14x and a current ratio of 3.13x, with a market beta of 0.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Guangzhou Kingmed Diagnostics Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guangzhou Kingmed Diagnostics Group (603882) the key facts are: market cap ¥12.6B, revenue ¥6.0B, 52-week range 21.5-40.68. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Guangzhou Kingmed Diagnostics Group's full fundamentals live
Get Guangzhou Kingmed Diagnostics Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.